Abstract
Purpose
Many studies have analyzed the cost-effectiveness of implantable cardioverter defibrillators (ICDs), but hospital costs have not been as thoroughly reported. This study reviewed the associated hospital costs for non-surgical patients who received ICDs from 2015 to 2019.
Methods
We performed a retrospective single-center analysis of patients who received an ICD between 2015 and 2019. ICD cost was analyzed with respect to time using linear regression t-test analysis.
Results
For 304 patients, we trended cost of the devices over time. 168 (55.2%) cases were single-chamber devices, 53 (17.4%) were dual-chamber, 59 (19.4%) were cardiac resynchronization therapy-defibrillators (CRT-D), and 24 (7.9%) were subcutaneous devices. The cost of all ICDs decreased by -$1.82/day (p<0.001), R2 = 0.056. By type, cost of single-chamber devices decreased by -$2.56/day (p<0.001), R2 = 0.47, dual-chamber ICD by -$3.50/day (p<0.001), R2 = 0.51, CRT-D by -$4.07/day (p<0.001), R2 = 0.47, and subcutaneous by -$3.33/day (p<0.001), R2 = 0.83.
Conclusion
This is the first detailed analysis of ICD costs that we are aware of. The cost of all ICDs decreased modestly and became much greater when categorized by type. Overall hospital cost associated with ICD implantation did not show a significant trend, but total supply cost showed a significant decrease over time.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Availability of data and material
Raw data were generated at the University of Maryland Medical Center. Derived data supporting findings of this study are available from the corresponding author (JN) on request
References
Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46–e215.
2013 ACCF/AHA guideline for the management of heart failure. WRITING COMMITTEE MEMBERS, Clyde W. Yancy, MD, MSc, FACC, FAHA, Chair, Mariell Jessup, MD, FACC, FAHA, Vice Chair, Biykem Bozkurt, MD, PhD, FACC, FAHA, Javed Butler, MBBS, FACC, FAHA, Donald E. Casey, Jr, MD, MPH, MBA, FACP, FAHA, Mark H. Drazner, MD, MSc, FACC, FAHA, Gregg C. Fonarow, MD, FACC, FAHA, Stephen A. Geraci, MD, FACC, FAHA, FCCP, Tamara Horwich, MD, FACC, James L. Januzzi, MD, FACC, Maryl R. Johnson, MD, FACC, FAHA, Edward K. Kasper, MD, FACC, FAHA, Wayne C. Levy, MD, FACC, Frederick A. Masoudi, MD, MSPH, FACC, FAHA, Patrick E. McBride, MD, MPH, FACC, John J.V. McMurray, MD, FACC, Judith E. Mitchell, MD, FACC, FAHA, Pamela N. Peterson, MD, MSPH, FACC, FAHA, Barbara Riegel, DNSc, RN, FAHA, Flora Sam, MD, FACC, FAHA, Lynne W. Stevenson, MD, FACC, W.H. Wilson Tang, MD, FACC, Emily J. Tsai, MD, FACC, and Bruce L. Wilkoff, MD, FACC, FHRS.
Patel S, et al. Financial overview of an LVAD program under Global Bundled Payment Model. J Cardiac Fail. 25(8):S165.
Mushlin AI, Hall WJ, Zwanziger J, Gajary E, Andrews M, Marron R, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation. 1998;97(21):2129–35. https://doi.org/10.1161/01.cir.97.21.2129.
Larsen G, Hallstrom A, McAnulty J, Pinski S, Olarte A, Sullivan S, et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation. 2002;105(17):2049–57. https://doi.org/10.1161/01.cir.0000015504.57641.d0.
Noyes K, Veazie P, Hall WJ, Zhao H, Buttaccio A, Thevenet-Morrison K, et al. Cost-effectiveness of cardiac resynchronization therapy in the MADIT-CRT trial. J Cardiovasc Electrophysiol. 2013;24(1):66–74. https://doi.org/10.1111/j.1540-8167.2012.02413.x.
van Welsenes GH, Borleffs CJ, van Rees JB, Atary JZ, Thijssen J, van der Wall EE, et al. Improvements in 25 years of implantable cardioverter defibrillator therapy. Neth Hear J. 2011;19(1):24–30.
Drastic falls in cost are powering another computer revolution. (n.d.). The Economist.
Gold MR, Padhiar A, Mealing S, Sidhu MK, Tsintzos SI, Abraham WT. Economic value and cost-effectiveness of cardiac resynchronization therapy among patients with mild heart failure: projections from the REVERSE long-term follow-up. JACC Heart Fail. 2017;5(3):204–12. https://doi.org/10.1016/j.jchf.2016.10.014.
Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353(14):1471–80.
Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med. 1998;13(10):716–7.
Pauker SG, Estes NA, Salem DN. Preventing sudden cardiac death: can we afford the benefit. Ann Intern Med. 2005;142(8):664–6. https://doi.org/10.7326/0003-4819-142-8-200504190-00015.
Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, et al. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med. 2001;135(10):870–83. https://doi.org/10.7326/0003-4819-135-10-200111200-00007.
Acknowledgments
All authors made a substantial contribution to the study. The study was designed by Dr. Jonathan Na, Dr. Jeffrey Rottman, and Michael Sokolow. Financial data was acquired by Michael Sokolow, and further demographic data was gathered by Dr. Jonathan Na, Dr. Paul Han, Dr. James Childress, and Dr. Sonika Patel. Dr. Na, Dr. Patel, and Dr. Rottman contributed to the analysis and interpretation of data. The article was drafted by Dr. Na and revisions were provided by Dr. Rottman and Dr. Patel. Dr. Rottman provided study oversight and final approval of the article submitted. All authors have read the final article and have approved it for submission.
Funding
No funding was used for the study.
Author information
Authors and Affiliations
Contributions
All authors have read and approved of the manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
This manuscript is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder.
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Na, J.S., Sokolow, M., Childress, J. et al. Recent temporal trends in hospital costs for non-surgical patients receiving implantable cardioverter defibrillators. J Interv Card Electrophysiol 63, 231–237 (2022). https://doi.org/10.1007/s10840-021-00956-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10840-021-00956-6